Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This won't happen. The government is in bed with BP.
$HALB
There is one way to stop big pharma from shutting this down.
I NEVER thought I would say this but the government needs to get involved and see this process through.
Make sure it does not get swept under the rug.
BP doesn't want things to work, whether from Halberd or from anyone else. This would heal and cure people. BP wants people to remain sick so they can continue selling medications to them. Business first!! It's a racket.
$HALB
Sad that the process works so well on so many different levels and big pharma will try to suppress it...These treatments seem to be a no brainer and should be fast tracked into the medical world. But there is a lot of money to be lost here with big pharma and they will resist as much as they can. I would volunteer for treatments today...no side effects here big pharma!! $HALB
OTC DISCLOSURE & NEWS SERVICE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Press Release | 02/08/2023
Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus with the assistance of student scholar lab assistants
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "The students have become quite adept at conjugating the necessary antibodies to the metallic nanoparticles and combining them with the bacteria under test, in preparation for laser exposure in Dr. Sturrus' lab. The students, with appropriate training, have been able to meticulously prepare the various strains of bacteria for laser exposure as well as assessing the degree of bacteria elimination after laser exposure. The really exciting aspect of this research is that we have been able to eliminate a variety of bacteria using the same antibody due to its affinity to a wide range of bacteria."
"The enthusiasm of these students and dedication to the project is nothing like I have ever seen," added Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department. The Halberd research project to extracorporeally eradicate target antigens through laser micro-heating provides the students with a great opportunity to experience real world applications of the concepts that they learn in the classroom."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The significance of Halberd's achievements in eradicating antibiotic resistant bacteria in ten minutes or less exposure to laser emissive energy compares favorably to the current standard of care of oral or injected antibiotic administration for up to ten days of required treatment. We intend to continue demonstrating the superiority of Halberd's technology by eradicating additional strains of Escherichia coli, Candida auris, Salmonella, Shigella, pneumococcus, etc. We believe that Halberd's patented advancement in the treatment of antibiotic-resistant bacteria could revolutionize future medicine worldwide, and we intend to prove it. We have yet to encounter an antigen that we have not been able to successfully eradicate with our patented process. Moreover, we have the flexibility of a multiplicity of eradication methods - laser, chemical bonding and radio frequency, each safely administered extracorporeally."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
I can feel it ready to run! :)
form t: buy 1,500,000 at 0.010725
Volume picking up! Hoping for PR soon regarding resistant bacteria samples given to $HALB by the CDC. That will be a game changer!
Beautiful ending!!
Have a good weekend everyone.
If you have watched football recently, you see that head trauma is now being taken seriously lately. Bet they would be willing to try the nasal spray. :)
Small Ball Ask taps, with weak Bid Support.
They need weekly PR's to get this moving. Anything is better then nothing.
Funding in place. Huge volume today! Blast off.
may develop treatmental chips for some diseases or conditions in the very next future
#BreakingNews $HALB Animal Tests at #MSU To Develop Nasal Spray for Blocking Negative Effectives of Head Trauma
https://thestreetreports.com/halberd-corporation-otcmktshalb-animal-testing-mississippi-state-university-for-developing-nasal-spray-that-blocks-negative-effects-of-head-trauma/
Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma
Press Release | 01/31/2023
Tests to be scheduled at Mississippi State University
JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. Russell Carr, of the College of Veterinary Medicine.
Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved.
Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "We have been very impressed by the protocol for testing traumatic brain injury in animals by the professors at Mississippi State University. What sets Halberd's nasal spray treatment apart is the ability to administer the treatment soon after injury in any setting, thus reducing the potential for serious permanent neurological damage."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Selecting a source for animal testing of our anti-traumatic brain injury nasal spray was a very difficult process. Many universities we met with simply didn't have the process, experience, or expertise to conduct the tests in a manner that would yield our desired results. Mississippi State University has developed the procedures and delivered a test protocol that meets Halberd's rigid specifications. We look forward to a successful program with Mississippi State University."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Looks like it is. :)
Good volume yesterday and today. Hope the snowball keeps rolling downhill!
We're lucky enough to have loaded up while most remain unaware. Just sit back and see it develop. :)
Just ONE successful animal test result and this goes to the moon.
Way way up. And no one knows about it
MSU's animal testing and CDC samples equals up, up and away!! This is serious stuff.
Yes, probably last year was casual discussions about how it all works. This PR making it official. Contracts signed ??, No doubt.
Just read the PR that you referred to. I guess $HALB and MSU were in discussions all this time and the results of the discussions will be to pursue animal testing.
#BreakingNews Halberd $HALB Agrees to Animal Testing at Mississippi State University #MSU
Halberd Agrees to Animal Testing at Mississippi State University
JACKSON CENTER, PA January 24, 2023 Halberd Corporation's (OTC: HALB) has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory. Read more
https://finance.yahoo.com/news/halberd-agrees-animal-testing-mississippi-130000516.html
See PR on June 8, 2022. Discussions started with MSU and FDA certification required.
Wasn't there an agreement to do this testing between $HALB and MSU last year?
$HALB Halberd Agrees to Animal Testing at Mississippi State University
https://www.accesswire.com/736412/halberd-agrees-to-animal-testing-at-mississippi-state-university
College of Veterinary Medicine to conduct testing
JACKSON CENTER, PA / ACCESSWIRE / January 24, 2023 / Halberd Corporation's (OTC PINK:HALB) has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory.
The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project. The project will be investigating the effectiveness of novel therapeutic measures that are under development for combating the damaging effects of traumatic brain injury.
Dr. Russell Carr in the College of Veterinary Medicine stated, "My colleagues and I at the University are excited about the potential that the outcomes will have and the opportunity to collaborate with the Halberd Corporation."
Details on scope and timing to follow
Ugly shit if you have a personal ethical standard....
Once you get money like MMs, HALB becomes cute shit.
Shell history is important:
https://investorshub.advfn.com/boards/memberpoststoboard.aspx?user=8777&boardid=20228&page=20
HALB - Decades of lies..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=89699917
HALB is a shit shell with a shitty history.
Trace my posting history.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=91270588
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=88526160
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=89709783
Can’t argue that. If they actually pulled off a medical miracle, I’d happily eat my words.
You might be right but it's all a gamble isn't it? Imagine if it panned out? :)
Bled off a few more this afternoon. This low volume rise is not sustainable. Only volume gives a real push.
JMO
Is it just me or does it seem to be taking a long time getting the animal testing going?
up step by step, but no volume?
$HALB terrific bounce back chart, from.005's earlier this week to yesterday's close at .0082. Let's see if we can make a run at the 50 DMA of .0098 to end this week.
https://stockcharts.com/h-sc/ui?s=halb
Was this a long term gap ,fill from October 2020 when HALB went 0058 to 06 in a week? I remember Scottrade didn't want to sell this ticker in early October 2020...
Volume comes in and money will be made.
(responsible mod: Bill Moynihan)
Halberd Corp. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
Halberd holds the exclusive rights to 4 granted U.S. Patents, no. 9,216,386 no. 8,758,287 and no. 11,186,629, no. 8,865,733
Halberd Corporation is a biotechnology company and with its partners (Dr. Qiang Shawn Chen and his team at Arizona State University; Dr. William Sturrus and his team at Youngstown State University; Dr. Richard Carr and his team at Mississippi State University), is developing an extra-corporeal (out of the body) treatment against PTSD, CTE, Alzheimer's Disease and other virusses and diseases. With the use of antibodies the disease antigens is targeted. Using radiofrequency / laser technology the "antibody-metallic moiety-antigens complex" is destroyed/eradicated. All based on 4 granted patents and 22 pending provisional/non-provisional (some PCT) patent applications.
2024: In close cooperation with partner (revenue sharing agreement in place) AthenaGTX, Halberd Corp is working on contracts from the military, to develop treatments to tackle Traumatic Brain Injury/TBI (patent pending nasal spray) and Post Traumatic Stress Syndrome/PTSD (patented Low-Dose-Naltrexone product).
CEO William Hartman: "The principal competitive Alzheimer's drug treatment available today eliminates 5-15% of Beta Amyloid after one month of treatment costing over $50,000 per year. Halberd's extracorporeal process eradicates 100% within just 10 minutes."
JACKSON CENTER, PA / ACCESSWIRE / March 14, 2023 / Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd's incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples previously provided by the CDC.
JACKSON CENTER, PA / ACCESSWIRE / September 6, 2023 / Halberd Corporation's (OTC PINK:HALB) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Anecdotal data in preliminary testing reveals a 20% reduction in Neuron Specific Enolase and a 50% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group.
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd's proprietary nasal spray for suppressing the effects of traumatic brain injury (TBI).
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2023 / Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd's patented low dose naltrexone combo product(s) worldwide. The agreement also allows CrodenHealth.com right of first refusal regarding similar rights to future products in Halberd's development pipeline.
JACKSON CENTER, PA / ACCESSWIRE / January 10, 2024 / Halberd Corporation (OTC-PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |